These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32479135)

  • 1. DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity.
    Hunt DWC; Ivanova IA; Dagnino L
    Tissue Barriers; 2020 Jul; 8(3):1765633. PubMed ID: 32479135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling.
    Li H; Li J; Zhang X; Feng C; Fan C; Yang X; Zhang R; Zhu F; Zhou Y; Xu Y; Liu H; Tang W
    Biochem Pharmacol; 2020 Jul; 177():113958. PubMed ID: 32251674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
    Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
    J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
    Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
    Schafer PH; Adams M; Horan G; Truzzi F; Marconi A; Pincelli C
    Drugs R D; 2019 Dec; 19(4):329-338. PubMed ID: 31598889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
    Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
    J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
    Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
    Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
    Andoh T; Kuraishi Y
    J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
    Kubota-Ishida N; Kaji C; Matsumoto S; Wakabayashi T; Matsuhira T; Okura I; Cho N; Isshiki S; Kumura K; Tabata Y
    Eur J Pharmacol; 2024 Jan; 962():176202. PubMed ID: 37996010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of orismilast, a potent and selective PDE4 inhibitor.
    Silverberg JI; French LE; Warren RB; Strober B; Kjøller K; Sommer MOA; Andres P; Felding J; Weiss A; Tutkunkardas D; Skak-Nielsen T; Guttman E
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):721-729. PubMed ID: 36527389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeic acid reduces cutaneous tumor necrosis factor alpha (TNF-α), IL-6 and IL-1β levels and ameliorates skin edema in acute and chronic model of cutaneous inflammation in mice.
    Zhang M; Zhou J; Wang L; Li B; Guo J; Guan X; Han Q; Zhang H
    Biol Pharm Bull; 2014; 37(3):347-54. PubMed ID: 24583856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways.
    Xu J; Duan X; Hu F; Poorun D; Liu X; Wang X; Zhang S; Gan L; He M; Zhu K; Ming Z; Chen H
    J Dermatol Sci; 2018 Feb; 89(2):127-135. PubMed ID: 29137840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory Effects of a Novel Chrysin-Derivative, CPD 6, on Acute and Chronic Skin Inflammation.
    Yu CH; Suh B; Shin I; Kim EH; Kim D; Shin YJ; Chang SY; Baek SH; Kim H; Bae ON
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31141897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
    Hiyama H; Arichika N; Okada M; Koyama N; Tahara T; Haruta J
    J Pharmacol Exp Ther; 2023 Jul; 386(1):45-55. PubMed ID: 37041087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genistein suppresses psoriasis-related inflammation through a STAT3-NF-κB-dependent mechanism in keratinocytes.
    Wang A; Wei J; Lu C; Chen H; Zhong X; Lu Y; Li L; Huang H; Dai Z; Han L
    Int Immunopharmacol; 2019 Apr; 69():270-278. PubMed ID: 30743203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory, anti-proliferative and anti-psoriatic potential of apigenin in RAW 264.7 cells, HaCaT cells and psoriasis like dermatitis in BALB/c mice.
    Singh VK; Sahoo D; Agrahari K; Khan A; Mukhopadhyay P; Chanda D; Yadav NP
    Life Sci; 2023 Sep; 328():121909. PubMed ID: 37414141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
    Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
    Song Z; Huang YY; Hou KQ; Liu L; Zhou F; Huang Y; Wan G; Luo HB; Xiong XF
    J Med Chem; 2022 Mar; 65(5):4238-4254. PubMed ID: 35188767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical application of glycolic acid suppresses the UVB induced IL-6, IL-8, MCP-1 and COX-2 inflammation by modulating NF-κB signaling pathway in keratinocytes and mice skin.
    Tang SC; Liao PY; Hung SJ; Ge JS; Chen SM; Lai JC; Hsiao YP; Yang JH
    J Dermatol Sci; 2017 Jun; 86(3):238-248. PubMed ID: 28330776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.